IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM Jackson, C., Choi, J., Zhang, J., Piotrowski, A., Walbert, T., Desai, A., Ahluwalia, M., Nabors, B., Ye, X., Desideri, S., Fisher, J., Wen, P., Grossman, S., Smith, K., Pardoll, D., Lim, M. OXFORD UNIV PRESS INC. 2019: 122

View details for Web of Science ID 000509478702175